GlassScriptPhysician profile
Ronald N Nettey
NPI 1386055499
$1,930.06
in general payments reported to CMS, 2019-2025
27 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $212 · 2021: $115 · 2022: $152 · 2023: $285 · 2024: $355 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $131.61 | 2019-2023 | Mounjaro |
| Gilead Sciences, INC. | $124.36 | 2019-2021 | |
| Pfizer INC. | $123.68 | 2019-2024 | |
| Abbvie INC. | $106.96 | 2019-2023 | |
| Astellas Pharma US INC | $100.63 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.51 | 2019-2020 | |
| Boston Scientific Corporation | $97.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.87 | 2024 | |
| Glaxosmithkline, LLC. | $77.77 | 2022-2025 | Shingrix, Arexvy |
| Heartflow, INC. | $72.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $72.33 | 2019-2020 | |
| Abbott Laboratories | $58.90 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $55.61 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $49.31 | 2019-2023 | Austedo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.63 | 2019-2024 | Evenity, Prolia |
| Dexcom, INC. | $42.44 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $36.69 | 2020-2021 | |
| Genentech USA, INC. | $34.39 | 2019 | |
| Endo Pharmaceuticals INC. | $34.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.81 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $18.90 | 2021 | |
| Shire North American Group INC | $15.55 | 2019 | |
| Sumitomo Pharma America, INC. | $14.29 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $14.19 | 2019 | |
| Sanofi Pasteur INC. | $13.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Nettey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.